One study showed that NSCLC patients with TP53 missense mutations had significantly shorter PFS treated with first-line EGFR-TKI therapy (HR 1.91, CI 1.01–3.60, P=0.04) (39). This evidence concerns the gene TP53 and non-small cell lung carcinoma.